Hence, we are confident that in view of its favorable preclinical data, 68Ga‐TRAP(SDM17)3 can contribute to the improvement of healthcare schemes for diagnosis and therapy of carcinomas as well as other conditions associated with αvβ6 integrin dependent dysregulation of the TGF‐β signaling pathway, such as fibrotic diseases. The gene discussed is TGFB1; the disease is carcinoma.